Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 7, 2010, Pages 1059-1064

  Hashimoto, Kenji ^a   Takashima, Atsuo ^a   Nagashima, Kengo ^b   Okazaki, Shun Suke ^a   Nakajima, Takako Eguchi ^a   Kato, Ken ^a   Hamaguchi, Tetsuya ^a   Yamada, Yasuhide ^a   Shimada, Yasuhiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b JOSAI UNIVERSITY   (Japan)

Author keywords

Advanced gastric cancer; Prognostic factor; Second line chemotherapy; Survival; Time to progression

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; C REACTIVE PROTEIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; IRINOTECAN; METHOTREXATE; MITOMYCIN; MITOMYCIN C; PACLITAXEL; PROSTAGLANDIN SYNTHASE; TAXANE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CONTINUOUS INFUSION; FEMALE; GASTRECTOMY; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MONOTHERAPY; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; STOMACH CANCER; SURVIVAL TIME; TUMOR DIFFERENTIATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RISK FACTORS; STOMACH NEOPLASMS; YOUNG ADULT;

EID: 77953231301     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-009-0752-8     Document Type: Article

References (21)

1. J Bellmunt J Albanell L Paz-Ares MA Climent JL Gonzalez-Larriba J Carles JJ de la Cruz V Guillem E Diaz-Rubio H Cortes-Funes J Baselga 2002 Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine Cancer 95 751 757 10.1002/cncr.10762 1:CAS:528:DC%2BD38Xms1Shtbk%3D 12209718 (Pubitemid 34839666)
2. N Boku A Ohtsu Y Shimada K Shirao S Seki H Saito Y Sakata I Hyodo 1999 Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer J Clin Oncol 17 319 323 1:CAS:528:DyaK1MXltVyrtg%3D%3D 10458249
3. N Boku S Yamamoto H Fukuda K Shirao T Doi A Sawaki W Koizumi H Saito K Yamaguchi H Takiuchi J Nasu A Ohtsu 2009 Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study Lancet Oncol 10 1063 1069 10.1016/S1470-2045(09)70259-1 1:CAS:528:DC%2BD1MXhtlGit7bI 19818685
4. V Catalano F Graziano D Santini S D'Emidio AM Baldelli D Rossi B Vincenzi P Giordani P Alessandroni E Testa G Tonini G Catalano 2008 Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? Br J Cancer 99 1402 1407 10.1038/sj.bjc.6604732 1:CAS:528:DC%2BD1cXhtlSktb%2FF 18971936
5. I Chau AR Norman D Cunningham JS Waters J Oates PJ Ross 2004 Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data J Clin Oncol 22 2395 2403 10.1200/JCO.2004.08.154 15197201 (Pubitemid 41121931)
6. B Glimelius K Ekstrom K Hoffman W Graf PO Sjoden U Haglund C Svensson LK Enander T Linne H Sellstrom R Heuman 1997 Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer Ann Oncol 8 163 168 10.1023/A:1008243606668 1:STN:280: DyaK2s3kslGqug%3D%3D 9093725 (Pubitemid 27112884)
7. W Ichikawa Y Sasaki 2006 Correlation between tumor response to first-line chemotherapy and prognosis in advanced gastric cancer patients Ann Oncol 17 1665 1672 10.1093/annonc/mdl174 1:STN:280:DC%2BD28njtlKltA%3D%3D 16873435 (Pubitemid 44687335)
8. L Janisch R Mick RL Schilsky NJ Vogelzang S O'Brien M Kut MJ Ratain 1994 Prognostic factors for survival in patients treated in phase I clinical trials Cancer 74 1965 1973 10.1002/1097-0142(19941001)74:7<1965:AID- CNCR2820740723>3.0.CO;2-1 1:STN:280:DyaK2czmtlKltA%3D%3D 8082103
9. F Kamangar GM Dores WF Anderson 2006 Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world J Clin Oncol 24 2137 2150 10.1200/JCO.2005.05.2308 16682732 (Pubitemid 46655601)
10. Y Kodera S Ito Y Mochizuki S Fujitake K Koshikawa Y Kanyama T Matsui H Kojima T Takase N Ohashi M Fujiwara J Sakamoto N Akimasa 2007 A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study) Anticancer Res 27 2667 2671 1:CAS:528:DC%2BD2sXpvFChsbY%3D 17695430 (Pubitemid 47227980)
11. W Koizumi H Narahara T Hara A Takagane T Akiya M Takagi K Miyashita T Nishizaki O Kobayashi W Takiyama Y Toh T Nagaie S Takagi Y Yamamura K Yanaoka H Orita M Takeuchi 2008 S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9 215 221 10.1016/S1470-2045(08)70035-4 1:CAS:528:DC%2BD1cXivVaqtb4%3D 18282805
12. J Lee T Lim JE Uhm KW Park SH Park SC Lee JO Park YS Park HY Lim TS Sohn JH Noh JS Heo CK Park S Kim WK Kang 2007 Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma Ann Oncol 18 886 891 10.1093/annonc/mdl501 1:STN:280: DC%2BD2s3ns1Klsg%3D%3D 17298958 (Pubitemid 47054086)
13. C Louvet F Carrat F Mal M Mabro K Beerblock JC Vaillant J Cady T Andre E Gamelin A de Gramont 2003 Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen) Cancer Invest 21 14 20 10.1081/CNV-120016399 1:CAS:528: DC%2BD3sXisF2mtrg%3D 12643005 (Pubitemid 36292503)
14. A Ohtsu Y Shimada K Shirao N Boku I Hyodo H Saito N Yamamichi Y Miyata N Ikeda S Yamamoto H Fukuda S Yoshida 2003 Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205) J Clin Oncol 21 54 59 10.1200/JCO.2003.04.130 1:CAS:528:DC%2BD2cXpsVWru7k%3D 12506170
15. S Pyrhonen T Kuitunen P Nyandoto M Kouri 1995 Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer Br J Cancer 71 587 591 1:STN:280:DyaK2M7os1ertg%3D%3D 7533517
16. P Ross M Nicolson D Cunningham J Valle M Seymour P Harper T Price H Anderson T Iveson T Hickish F Lofts A Norman 2002 Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer J Clin Oncol 20 1996 2004 10.1200/JCO.2002.08.105 1:CAS:528: DC%2BD38XjvVKmsrw%3D 11956258 (Pubitemid 34413593)
17. DJ Sargent CH Kohne HK Sanoff BM Bot MT Seymour A de Gramont R Porschen LB Saltz P Rougier C Tournigand JY Douillard RJ Stephens A Grothey RM Goldberg 2009 Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine-first-line treatment trials using individual data from patients with metastatic colorectal cancer J Clin Oncol 27 1948 1955 10.1200/JCO.2008.20.2879 19255311
18. K Shirao Y Shimada H Kondo D Saito T Yamao H Ono T Yokoyama H Fukuda M Oka Y Watanabe A Ohtsu N Boku T Fujii Y Oda K Muro S Yoshida 1997 Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer J Clin Oncol 15 921 927 1:CAS:528:DyaK2sXitFCgs7o%3D 9060529
19. A Sulkes J Smyth C Sessa LY Dirix JB Vermorken S Kaye J Wanders H Franklin N LeBail J Verweij 1994 Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group Br J Cancer 70 380 383 1:STN:280:DyaK2czjtFegsw%3D%3D 7914428
20. U Vanhoefer P Rougier H Wilke MP Ducreux AJ Lacave E Van Cutsem M Planker JG Santos P Piedbois B Paillot H Bodenstein HJ Schmoll H Bleiberg B Nordlinger ML Couvreur B Baron JA Wils 2000 Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group J Clin Oncol 18 2648 2657 1:CAS:528:DC%2BD3cXls12iurk%3D 10894863
21. Y Yamamura T Nakajima K Ohta A Nashimoto K Arai M Hiratsuka M Sasako Y Kodera M Goto 2002 Determining prognostic factors for gastric cancer using the regression tree method Gastric Cancer 5 201 207 10.1007/s101200200035 12491077 (Pubitemid 36605882)